ALG9 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ALG9 gene in the human Jurkat T-lymphocyte host line. This loss-of-function model leverages CRISPR/Cas9-mediated gene disruption to eliminate functional ALG9 expression across a heterogeneous cell pool, enabling studies of N-glycan biosynthesis and its role in immune cell biology. The polyclonal nature preserves the diversity of editing outcomes typical of a mixed knockout population, making it suitable for bulk analysis of glycosylation-dependent phenotypes without clonal selection artifacts.
The Jurkat cell line, derived from peripheral blood of a patient with acute T-cell leukemia, is a widely established model for T-cell signaling, apoptosis, and immune response mechanisms. Its rapid growth and well-characterized signaling pathways, including TCR-mediated activation and downstream effectors, provide a robust platform for interrogating how post-translational modifications influence lymphocyte function. The leukemic origin also renders Jurkat cells valuable for exploring glycocalyx remodeling in malignant transformation and drug resistance.
ALG9 encodes an alpha-1,2-mannosyltransferase that catalyzes the transfer of mannose from GDP-mannose to the dolichol-linked oligosaccharide precursor in the endoplasmic reticulum, a critical step in the assembly of the lipid-linked core glycan for N-glycosylation. Its activity is integrated into the broader glycosylation machinery through interactions with ALG12, ALG6, ALG8, and the dolichol phosphate cycle, while upstream stress sensors such as XBP1, ATF6, ATF4, and the IRE1/PERK branches of the unfolded protein response transcriptionally regulate ALG9 expression. Downstream targets include mature N-glycosylated proteins like the T-cell receptor (TCR), CD3 complex, and integrins, whose proper folding and function depend on correct glycan processing. Disruption of ALG9 therefore impairs N-glycan maturation, leading to accumulation of misfolded glycoproteins, engagement of calnexin/calreticulin quality control, and activation of ER-associated degradation pathways.
In the Jurkat T-cell context, ALG9 knockout directly compromises the glycosylation of immune receptors and adhesion molecules, providing a tangible model to dissect how aberrant N-glycans alter T-cell activation thresholds, signal transduction, and apoptotic sensitivity. This is particularly relevant for congenital disorders of glycosylation type IL, caused by ALG9 mutations, and for understanding how tumors exploit glycosylation changes to evade immune surveillance. The knockout system allows researchers to correlate specific glycan deficits with functional outcomes in a leukemic T-cell background, bridging molecular glycobiology and cancer immunology.
Typical research applications include lectin blotting and flow cytometry with lectins to profile cell-surface glycan alterations, western blotting for key glycoproteins such as TCR subunits, mass spectrometry-based N-glycomics for detailed structural analysis, T-cell activation assays measuring CD69 upregulation or IL-2 secretion, and apoptosis assays to assess ER stress sensitivity. The model is also suited for drug sensitivity screens targeting glycosylation or the unfolded protein response, and for glycocalyx engineering studies. For further details on validation data or custom applications, please contact Ascent Research.
